Rebalix
UBS · sheet of 10 September 2026
UBS · sheet of 10 September 2026ETF sheet · official issuer and register data
UBS SBI® Corporate ESG ETF CHF dis
CH0118923876 · CH0118923876 · CHF · domicile Switzerland
Bonds · Corporate CHF · Broad (all maturities) · GlobalSFDR art. 8
Index tracked: SBI® ESG Corporate Total Return
- TER
- 0.15%+ trans. 0.02%
- Fund size
- —
- Tracking difference
- −0.46%3-year avg
- 🇮🇹 tax rate
- —white list not published
- Replication
- Physical
- Income
- Distributingannual
- Duration
- 4.67 yrsmedium (3–7 years)
Launch 29 Nov 2010 · costs from the KID as of 26 Aug 2026
The fund’s objective — in the issuer’s words
From the Key Information Document (KID) · 2 Sept 2026
The investment objective of the subfund is to track the price and income performance of the SBI® ESG Corporate (TR) before costs. This subfund invests primarily in bonds from sustainable Swiss and foreign-domiciled companies in the Swiss Bond Index (SBI). This subfund promotes ecological and/or social characteristics, but does not pursue a sustainable investment objective. The fund will not engage in securities lending transactions. The fund's return depends primarily on the performance of the tracked index. The sub-fund's net income is distributed…
Performance since series start (in euro) — base 100
29 Nov 2010 → 8 Sept 2026 · dividends reinvested where declared by the issuer · converted at ECB rates
Returns in euro
| 1 year | −1.4% |
| 3 years | +8.2% |
| 5 years | +12.4% |
| 10 years | +4.0% |
| Since series start | +19.3% |
Risk · 1 / 3 / 5 years
| Volatility (ann.) | 2.00% | 2.17% | 3.28% |
| Max drawdown | −1.99% | −2.46% | −15.05% |
| Sharpe | -1.68 | -0.65 | -1.16 |
| Sortino | -1.96 | -0.79 | -1.43 |
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · CH0118923876 · CH01189238761
RebalixCH0118923876 · CH0118923876 · sheet of 10 September 2026
Tracking difference — year by year
Fund minus index, complete calendar years · fund with dividends reinvested by Rebalix on each ex-date (no issuer total-return series); index from the declared series
| Year | Fund | Index | TD |
|---|---|---|---|
| 2025 | +0.25% | +0.70% | −0.45% |
| 2024 | +4.48% | +4.95% | −0.47% |
| 2023 | +5.28% | +5.72% | −0.45% |
| 2022 | −9.22% | −9.14% | −0.08% |
| 2021 | −2.43% | −1.01% | −1.42% |
Fixed income — as declared by the issuer
Issuer page · 31 Jul 2026
Distributions · per share, in CHF
Frequency: annual · last 12 months: 0.00 CHF (0.00% of NAV) · last ex-date 5 Sept 2025
| Year | Payments | Total (CHF) | Dividend yield |
|---|---|---|---|
| 2025 | 1 | 0.5395 | +0.76% |
| 2024 | 1 | 0.4745 | +0.69% |
| 2023 | 1 | 0.286 | +0.44% |
| 2022 | 1 | 0.481 | +0.66% |
| 2021 | 1 | 1.339 | +1.77% |
Dividend yield: the year’s distributions over the share value (NAV) at the start of the year.
Listing venues
ESMA register (FIRDS) and official exchange lists
No EU listing in the ESMA register.
Official documents
Clickable links in the PDF
The live sheet, always up to date
rebalix.com/en/etf/CH0118923876
Series, distributions, holdings and documents refresh daily.
rebalix.com/en/etf/CH0118923876
Series, distributions, holdings and documents refresh daily.
Sheet produced on 10 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV and total-return series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.
Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.
Rebalix · CH0118923876 · CH01189238762